Qure.ai stock
Private-market facts for current and former Qure.ai employees researching their stock.
Overview
Qure.ai develops AI-powered medical imaging solutions for radiology, particularly chest X-ray and CT scan analysis for tuberculosis and stroke detection.
Selling Qure.ai shares
Why shareholders consider selling
Shareholders in Qure.ai may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Qure.ai does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell Qure.ai stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Qure.ai shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of Qure.ai shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Series C round can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for Qure.ai shareholders
Exploring equity in Qure.ai often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
Qure.ai most recently raised a Series C round . Total funding raised to date is approximately $95M.
Lead investors in this round include Sequoia Capital.
Founders & company background
Qure.ai was founded in 2016 by Prashant Warier, Pooja Rao and is headquartered in Mumbai, India.
Investors
Industry
Similar private companies
Latest Qure.ai news
Frequently asked questions
- Is Qure.ai still a private company?
- Yes, Qure.ai is currently a private company.
- What is Qure.ai's latest funding round?
- Qure.ai's most recent known round is Series C.
- What is Qure.ai's valuation?
- Qure.ai's valuation has not been publicly disclosed.
- Who are the investors in Qure.ai?
- Notable investors include Sequoia Capital.
- Can I sell my Qure.ai stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Qure.ai stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · Qure.ai data compiled from funding disclosures, investor announcements, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.